Pharmafile Logo
Pharmafocus logo
Advanced Search

Galapagos

Showing 10 posts of 10 posts found.

Galapagos announces leadership changes amid planned company split

April 22, 2025
Analytical & Laboratory Services, Research and Development CEO Appointment, Corporate, Galapagos, cell therapy

Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been …

Appointment

Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery

January 4, 2024
Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology

Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …

News
shutterstock_212432119

Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

October 31, 2019
Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …

News
gilead-sciences

Gilead invests $5.1 billion into Galapagos NV

July 15, 2019
Sales and Marketing Galapagos, Gilead, biotech, collaboration, deal, drug discovery, pharma

Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV. The collaboration will see Gilead invest $5.1 …

News
gilead-sciences

Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal

September 7, 2018
Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …

News
AbbVie

Galapagos and AbbVie in $405m cystic fibrosis deal

September 25, 2013
Research and Development, Sales and Marketing AbbVie, Galapagos, cystic fibrosis

News
Abbvie image

AbbVie and Galapagos extend deal

May 21, 2013
Sales and Marketing AbbVie, Crohn's, Galapagos

AbbVie and Belgian biotech Galapagos have bolted on a development programme for Crohn’s disease to the selective JAK1 inhibitor they …

News
roche image

Roche bins Galapagos tie-up

March 12, 2013
Sales and Marketing COPD, Galapagos, Roche

Roche has ended its three-year old alliance with Belgian drug discovery specialist Galapagos because of a ‘strategic change’. The companies …

News
Abbott image

Abbott buys into Galapagos’ RA candidate

February 29, 2012
Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF

Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …

News

Contract research news in brief

September 20, 2010
Research and Development Covance, Galapagos, MediData Solutions, MediSync BioServices, PPD, Quotient Bioresearch, i3

A round-up of recent news from the CRO sector, featuring updates from Covance, Quotient Bioresearch, PPD, i3, Galapagos, MediSync BioServices …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026